Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Pravin R. Chaturvedi
Observed names:
P Chaturvedi,
P. Chaturvedi,
Pravin Chaturvedi,
Pravin R Chaturvedi
Observed institutions:
Inserm,
Georgetown University,
SUNY Upstate Medical University,
Brown University,
Massachusetts General Hospital,
Hospices Civils de Lyon,
Napo Pharmaceuticals (United States),
Vertex Pharmaceuticals (United States)
show all 8
ORCID:
0009-0006-3830-6293
Observed ORCID:
0009-0006-3830-6293
OpenAlex ID:
A5111845671
Biologically erodable microspheres as potential oral drug delivery systems
1997
·
Edith Mathiowitz
, Jules S. Jacob
, et al.
·
Nature
·
822
Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease
2006
·
Robert B. Perni
, Susan J. Almquist
, et al.
·
Antimicrobial Agents and Chemotherapy
·
386
The future of drug development: advancing clinical trial design
2009
·
John Orloff
, Frank Douglas
, et al.
·
Nature Reviews Drug Discovery
·
158
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
1998
·
E K Rowinsky
, L Smith
, et al.
·
Journal of Clinical Oncology
·
145
A Nonimmunosuppressant FKBP-12 Ligand Increases Nerve Regeneration
1997
·
Bruce G. Gold
, Michelle Zeleny-Pooley
, et al.
·
Experimental Neurology
·
134
Prediction of pharmacokinetic properties using experimental approaches during early drug discovery
2001
·
Pravin R Chaturvedi
, Caroline J Decker
, et al.
·
Current Opinion in Chemical Biology
·
118
Metabolism of Amprenavir in Liver Microsomes: Role of CYP3A4 Inhibition for Drug Interactions
1998
·
Caroline J. Decker
, Leena M. Laitinen
, et al.
·
Journal of Pharmaceutical Sciences
·
112
Phase I and Pharmacokinetic Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination With Doxorubicin
2001
·
Ronald A. Peck
, Jan Hewett
, et al.
·
Journal of Clinical Oncology
·
107
A Novel Immunophilin Ligand: Distinct Branching Effects on Dopaminergic Neurons in Culture and Neurotrophic Actions after Oral Administration in an Animal Model of Parkinson's Disease
1998
·
L.C. Costantini
, P. Chaturvedi
, et al.
·
Neurobiology of Disease
·
104
Bioadhesive microspheres: III. An in vivo transit and bioavailability study of drug-loaded alginate and poly(fumaric-co-sebacic anhydride) microspheres
1997
·
D.E Chickering
, J.S Jacob
, et al.
·
Journal of Controlled Release
·
78
Oral administration of a nonimmunosuppressant FKBP-12 ligand speeds nerve regeneration
1998
·
Bruce G. Gold
, Michelle Zeleny-Pooley
, et al.
·
Neuroreport
·
58
Evaluation of Crofelemer in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome Patients
2008
·
Allen W. Mangel
, Pravin Chaturvedi
·
Digestion
·
48
Process Development and Scale-up Total Synthesis of Largazole, a Potent Class I Histone Deacetylase Inhibitor
2018
·
Qi-Yin Chen
, Pravin R. Chaturvedi
, et al.
·
Organic Process Research & Development
·
37
PDF
Stability Studies of Gabapentin in Aqueous Solutions
1992
·
Elena Zour
, Shahid A. Lodhi
, et al.
·
Pharmaceutical Research
·
34
Effect of neurophilin ligands on motor units in mice with SOD1 ALS mutations
2001
·
J. M. Shefner
, R. H. Brown
, et al.
·
Neurology
·
30
Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study
2024
·
Ragda Abdalla-Aslan
, Pierluigi Bonomo
, et al.
·
EClinicalMedicine
·
19
Practical Considerations for a Two-Stage Confirmatory Adaptive Clinical Trial Design and Its Implementation: ADVENT Trial
2014
·
Pravin R. Chaturvedi
, Zoran Antonijevic
, et al.
·
Statistics for biology and health
·
11
Pharmacokinetics and Safety of Single Oral Doses of VX‐366 (Isobutyramide) in Healthy Volunteers
1996
·
Lee R. Brettman
, Pravin R. Chaturvedi
·
The Journal of Clinical Pharmacology
·
6
Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs
2024
·
Michael Guy
, Andre Teixeira
, et al.
·
PLoS ONE
·
5
Healthcare utilization and costs associated with cancer-related diarrhea.
2021
·
Eric Roeland
, Lee S. Schwartzberg
, et al.
·
Journal of Clinical Oncology
·
5
The impact of cancer-related diarrhea on changes in cancer therapy patterns.
2021
·
Pablo C. Okhuysen
, Lee S. Schwartzberg
, et al.
·
Journal of Clinical Oncology
·
3
Characterizing unplanned resource utilization associated with cancer-related diarrhea.
2021
·
Lee S. Schwartzberg
, Eric Roeland
, et al.
·
Journal of Clinical Oncology
·
3
The impact of cancer-related diarrhea on changes in cancer therapy
2024
·
Abdullah Aleem
, Maya Charuni Sarihan
, et al.
·
Supportive Care in Cancer
·
2
PDF
Pharmacokinetics of Microparticulate Systems
2020
·
Pravin R. Chaturvedi
·
CRC Press eBooks
·
1
Abstract P1-02-15: Natural history including the incidence, severity and management of diarrhea in patients with breast cancer receiving abemaciclib and pertuzumab-based therapies with or without standard chemotherapy: Data from placebo arm of the OnTarget study
2025
·
Pablo C. Okhuysen
, Eric Roeland
, et al.
·
Clinical Cancer Research
Show more works
View as search
Works count:
35
Citation count:
2,427
H-index:
16
I10-index:
17
Year
Topic
Type
